No Data
No Data
Is ApicHope Pharmaceutical (SZSE:300723) Using Too Much Debt?
ApicHope Pharmaceutical (300723.SZ): ApicHope Pharmaceutical's biological product, injectable Yanhuoning and Shenmai drink (Dangshen formula) is expected to be selected for centralized volume procurement.
On December 31, Glonhue announced that ApicHope Pharmaceutical (300723.SZ) disclosed that its wholly-owned subsidiary ApicHope Biomedical Co., Ltd. (abbreviated as "ApicHope Biomedical") participated in the national centralized procurement conducted by the National Chinese Patent Medicine Joint Procurement Office. According to the document "Announcement of the Proposed Selected Results of the National Chinese Patent Medicine Procurement Alliance Centralized Procurement" published by the National Chinese Patent Medicine Joint Procurement Office on December 30, 2024, on the Hubei medical insurance service platform, ApicHope Biomedical's products, Injected Yanhu Ning and Shen Mai Yin (Dangshen formula), are proposed to be selected in this centralized procurement.
ApicHope Pharmaceutical (300723.SZ): The wholly-owned subsidiary's Innovative Drugs APH01727 tablet has received clinical trial approval from the USA FDA.
On December 23, GELONGHUI reported that ApicHope Pharmaceutical (300723.SZ) announced that recently, its wholly-owned subsidiary Guangzhou ApicHope Pharmaceutical Co., Ltd. received a letter from the USA Food and Drug Administration (FDA) regarding the approval of the clinical trial for the innovative drug APH01727 tablets, independently developed by the company's subsidiary. APH01727 tablets are a highly active and highly selective glucagon-like peptide-1 receptor agonist (GLP-1RA) developed by the company, aiming to be administered once daily.
ApicHope Pharmaceutical (300723.SZ): Wholly-owned subsidiary Lianrui Pharmaceutical has been recognized as a high-tech enterprise.
On December 17th, Gelonghui reported that ApicHope Pharmaceutical (300723.SZ) announced that according to the "Announcement on the Second Batch of High-tech Enterprises Filed for Recognition by Institutions in Guangdong Province for 2024" published by the National High-tech Enterprise Recognition Management Work Leading Group Office on December 17, 2024, the company's wholly-owned subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. (hereinafter referred to as "Lianrui Pharmaceutical") has been included in the second batch of high-tech enterprises filed for recognition by institutions in Guangdong Province for 2024. This is Lianrui Pharmaceutical's first time obtaining high-tech enterprise recognition, with the certificate number GR20.
The subsidiary of apichope pharmaceutical (300723.SZ), South China Vaccine, plans to sign a patent and technology transfer agreement for the influenza recombinant protein vaccine project.
Apichope Pharmaceutical (300723.SZ) announced that the company's board of directors has approved that the company's holding subsidiary guangdong South China Vaccine Co., Ltd...
Apichope Pharmaceutical (300723.SZ): Carbetocin oral solution for a new specification has been approved
apichope pharmaceutical (300723.SZ) announcement, the company's wholly-owned subsidiary Guangzhou apichope pharmaceutical Co., Ltd. (referred to as "apichope...